Latest statistics and disclosures from Abingworth's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMRN, Portola Pharmaceuticals, Supernus Pharmaceuticals, ALNY, OGXI. These five stock positions account for 89.34% of Abingworth's total stock portfolio.
- Added to shares of these 9 stocks: Portola Pharmaceuticals (+$30.50M), ALNY (+$9.69M), OGXI (+$5.92M), Cempra (+$5.59M), Zogenix, Anthera Pharmaceuticals, Hyperion Therapeutics, Gw Pharmaceuticals Plc ads, ZLCS.
- Started 9 new stock positions in ALNY, Cempra, Anthera Pharmaceuticals, Portola Pharmaceuticals, Hyperion Therapeutics, Gw Pharmaceuticals Plc ads, ZLCS, OGXI, Zogenix.
- Reduced shares in these 10 stocks: Clovis Oncology (-$26.90M), ALNY (-$12.53M), (-$11.66M), OGXI (-$6.83M), INCY (-$6.79M), ISIS, Zogenix, Anthera Pharmaceuticals, EXEL, Hyperion Therapeutics.
- Sold out of its positions in *alexza Pharmaceuticals, ALNY, Anthera Pharmaceuticals, Astex Pharmaceuticals, AVNR, Cardiome Pharma, Clovis Oncology, CRTX, ENMD, EXEL. Hyperion Therapeutics, INCY, ISIS, OGXI, ZLCS, Zogenix.
- As of June 30, 2013, Abingworth has $129.97M in assets under management (AUM). Assets under management dropped from a total value of $162.16M to $129.97M.
- Independent of market fluctuations, Abingworth was a net seller by $22.12M worth of stocks in the most recent quarter.
Abingworth portfolio companies for June 2013 quarter
|Ticker||Name||Portfolio Weight||Change||Share Count||Price||Last Trade|
|Gw Pharmaceuticals Plc ads||0.68||NEW||102200||8.60||0.00|
Past 13F-HR SEC Filings for Abingworth
- Abingworth 2013 Q1 - filed May 15, 2013
- Abingworth 2012 Q4 - filed Feb. 13, 2013
- Abingworth 2012 Q3 - filed Nov. 7, 2012
- Abingworth 2012 Q1 - filed May 14, 2012
- Abingworth 2011 Q4 - filed Feb. 7, 2012
- Abingworth 2011 Q3 - filed Nov. 14, 2011
- Abingworth 2011 Q1 - filed May 13, 2011
- Abingworth 2010 Q4 - filed Feb. 14, 2011